Early and sustained changes in bone metabolism after severe burn injury.
Vienna, Austria. In J Clin Endocrinol Metab, Feb 2016
During the early phase pronounced increases were observed for CTX, P1NP, sclerostin, DKK-1, BALP, FGF23 and iPTH levels, whereas 25-OH vitamin D, albumin, serum and ionized calcium levels decreased.
Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis.
Shenyang, China. In Ann N Y Acad Sci, Jan 2016
Recent clinical observations and animal studies demonstrate that Wnt signaling proteins and natural Wnt inhibitors, such as DKK1 and sclerostin, are likely to play important roles in the process of ankylosis in SpA, and could potentially serve as therapeutic targets for the treatment of SpA.
[Newly developed drugs to improve bone strength].
Tottori, Japan. In Clin Calcium, Dec 2015
In addition, new drugs with new action mechanisms such as cathepsin K inhibitor or anti-sclerostin antibody are also being developed and it has been reported that they have good potential to increase bone mineral density.
Serum and tissue biomarkers in aortic stenosis.
Athens, Greece. In Glob Cardiol Sci Pract, 2014
We prospectively studied the following serum BMs in 60 patients with CAVS and compared them to 20 healthy controls, free from any cardiac disease: Matrix metalloproteinases (MMP) 2 and 9 and tissue inhibitor of metalloproteinase 1 (TIMP1), which regulate collagen turnover, inflammatory factors, i.e. tumor necrosis factor a (TNFa), interleukin 2 (IL2), transforming growth factor β1 (TGF-β1) which regulates fibrosis, fetuin-A (fet-A), osteopontin (OPN), osteoprotegerin (OPG), sclerostin (SOST), and relaxin-2 (RL2) which positively or negatively regulate calcification.
New insights into treatment of osteoporosis in postmenopausal women.
Maastricht, Netherlands. In Rmd Open, 2014
New potential drugs for fracture prevention that uncouple bone resorption from bone formation include odanacatib, a specific inhibitor of cathepsin-K, the enzyme that degrades bone collagen type I, that inhibits bone resorption and only temporarily bone formation, and monoclonal antibodies against sclerostin (romosozumab, blosozumab), that stimulate bone formation and decrease bone resorption.
Role of Irisin on the bone-muscle functional unit.
Bari, Italy. In Bonekey Rep, 2014
Low-dose r-Irisin also increases osteopontin and decreases sclerostin synthesis but did not affect Uncoupling protein 1 expression in white adipose tissue, whose upregulation is known to cause browning of fat, when Irisin is administered at a higher dose.
Removing the bone brake.
Erlangen, Germany. In Cell Metab, 2014
Recently, McClung et al. (2014) found that neutralization of sclerostin, a potent inhibitor of bone formation, effectively increased bone mass in postmenopausal women.
Osteoporosis: now and the future.
Dresden, Germany. In Lancet, 2011
The most promising novel treatments include: denosumab, a monoclonal antibody for receptor activator of NF-κB ligand, a key osteoclast cytokine; odanacatib, a specific inhibitor of the osteoclast protease cathepsin K; and antibodies against the proteins sclerostin and dickkopf-1, two endogenous inhibitors of bone formation.